Labelling indices in human tumours: to apply corrections or not – that is the question

C Bergström, A Begg, R Palmqvist, A Waites and J Denekamp

Department of 1Oncology and 2Pathology, Umeå University, SE-901 85 Umeå, Sweden; and 3Department of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands

Summary

The advent of halogenated pyrimidines (bromodeoxyuridine, BrdU; idoxuridine, IdU) and antibodies to recognize them has opened new horizons for the measurement of proliferation in human tumours. These precursors of DNA can be given to patients and a single biopsy can be taken to measure in a flow cytometer both the fraction of labelled cells and their rate of movement through the S phase. From these two parameters the potential doubling time, \( T_{pot} \), can be calculated. To measure both parameters simultaneously a compromise is made in the time of assessing the labelling index (LI). LI should ideally be assessed after a very short interval, e.g. 0.5–1 h, to avoid the contaminating influence of any cells dividing between injection and biopsy. However, an interval of 4–8 h is considered necessary to assess \( T_s \) from the relative movement of cells through the S phase. Several techniques exist to correct for cell division if the interval is long. The simplest correction, which only corrects for the division of labelled cells, is most widely used. Downward correction factors of at least 10% are commonly applied, reducing the observed LI values. In this paper we illustrate graphically the dependence of the appropriate correction factor on various cell kinetic parameters. The duration of G2 is the most critical parameter for both the size and direction of any correction factor. The G2 phase has previously been shown to be about three times longer in human tumours than in rodents. If G2+M is as long as 6 h, the main artefact of the intervals between injection and biopsy up to 7 h is that the observed LI is too low because of division of unlabelled G2 cells. A correction of up to 10% is needed but in an upward direction. A nomogram of probable correction factors as a function of sampling interval is provided. We show from flow cytometric data that G2+M may be shorter than 4 h for head and neck tumours. It is recommended that the correction factor established by gating the flow histogram should always be checked against this nomogram, or that no correction factor should be applied. We have used this mathematical approach to re-evaluate two sets of published LI data for rectal and colorectal tumours. We question whether other of the published series of LI values gained with BrdU or IdU may also substantially underestimate the true LI values, if a simple gating procedure has been used in an attempt to reduce the impact of divided S phase cells.

Keywords: proliferation; human tumours; labelling index; colorectal cancers; IUDR

Techniques to measure the proliferation rate of human tumours in situ have been sought for decades. Historically, estimates were based on the fraction of mitoses visible in histological specimens. In the 1950s, radioactive precursors of DNA were used to identify the cells preparing for division and the four separate phases of the cell cycle were identified, G1, S, G2 and M (Howard and Pelc, 1953). This was followed in the 1960s by techniques to measure the cell cycle, the growth fraction and the rate of cell loss in order to provide a complete description of the growth characteristics of experimental and human tumours (reviewed in Steel, 1977). Unfortunately, these techniques required multiple biopsies and the DNA targeted radio-isotopes were not suitable for widespread use in humans, because of their genotoxic potential.

In the 1970s, flow cytometers were manufactured and the fraction of cells in the S phase could be identified without administering precursors, by staining cells for their DNA content and counting those between diploid and tetraploid DNA content. However, this does not give kinetic information about transit times and cannot distinguish between active and quiescent S phase cells. Eventually, in the early 1980s, non-radioactive halogenated precursors were developed that could, when bound into DNA, be identified using monoclonal antibodies with fluorescent tags (Gratzner et al, 1982; Dolbeare and Gray, 1983). It was realized that this provided the potential to measure both the fraction of cells actively synthesizing DNA and their rate of progress through the S phase from a single biopsy sample (Begg et al, 1985). It was called the relative movement assay. This made it possible, at last, to obtain from a single biopsy in patients the two independent parameters, \( T_s \) and labelling index (LI), that are needed to estimate the potential doubling time, \( T_{pot} \), of a tumour.

\[
T_{pot} = \lambda \cdot \frac{T_s}{LI} \quad (\text{Steel, 1977}) (1)
\]

\( \lambda \) is a correction factor for the non-linear age distribution, and is often arbitrarily (as in our centre) set at 0.8. There are, inevitably, a number of assumptions in applying this technique, and a certain degree of compromise in the time interval that must be used between labelling and sampling the cells. A very short interval (0.5–1.0 h) is optimal for determining LI, but an interval that is
about half $T_g$ is optimal for defining the relative movement of labelled S phase cells towards a G2 content of DNA. An interval of 4–8 h is generally recommended. For cells in vitro or in rodent tumours, this interval is much longer than the phases (G2 plus M). This interval would, in such systems, allow labelled cells to transit these phases and divide, thus adding extra labelled cells to the population. This potential artefact in the assessment of LI was recognized early on, and several methods have been offered to solve it. The first was a simple and practical gating procedure of the bivariate histogram (Begg et al, 1988). The labelled cells are assessed in the flow cytometry histogram, and a decision is made about which cells have transited G2 and mitosis and re-entered G1 as two cells. This group of cells is then gated and counted separately, divided by two and subtracted from both the labelled cells and the total cells to obtain a corrected LI (see Begg, 1989, for details). No account was taken of the division of unlabelled cells leaving G2 and doubling as they go through mitosis, because for cells in vitro and for animal tumours these phases are very short.

A modification of this formula was proposed by Brons et al (1992) to take into consideration the division of unlabelled G2 cells within an interval corresponding to G2+M. Although this is more accurate, the simple formula is more commonly applied. It has been pointed out that the simple (Begg) correction is inappropriate for very short sampling times or for histograms where there is not clear evidence of two separate sub-populations in the bivariate histograms (Wilson et al, 1988; Begg, 1989). However, in practice, in many centres as in ours it may be applied somewhat too frequently.

An alternative and more sophisticated approach is to use a much more complex mathematical treatment of the measured LI. This involves assumptions or prior knowledge about the phase duration and the form of the growth curves (White et al, 1990; Johansson et al, 1998). The mathematical correction is more accurate but appears somewhat complex and has not been widely adopted by flow cytometry operators.

In this paper we demonstrate graphically the correction factors that should theoretically be applied for various assumptions about phase durations. We show the consequences for different values of LI. We have used the same mathematical model as that of White et al (1990). We have then used this approach to re-evaluate two sets of flow cytometry data for colorectal cancers. We demonstrate the difference if the commonly used simple correction, or the mathematical formula based on best estimates of the duration of G2 and S in human tumours is applied.

**MATERIALS AND METHODS**

There are two parts to this study: a mathematical component, and a practical analysis of patient data.

**Mathematical modelling**

A flash label is assumed to be administered which marks only those cells actively synthesizing DNA. As the cells progress around the cell cycle, first unlabelled cells (originally in G2 and M phase) then labelled cells (originally in S phase) divide, and therefore the fraction of labelled cells ($f(t)$) varies with time. As described by White et al (1990), this fraction can be calculated at any time $t$ after labelling, according to

$$f(t) = \begin{cases} e^{t/T_g} & \text{if } t < T_g \smallskip \\ e^{t/T_g} e^{e^{t/T_g} - 1} & \text{if } T_g \leq t < T_g + T_{G2+M} \smallskip \\ e^{t/T_g} e^{e^{t/T_g} - 2} & \text{if } T_g + T_{G2+M} \leq t < T_g + T_{G2+M} + \frac{1}{2}T_s \smallskip \\ 2e^{t/T_g} e^{e^{t/T_g} - 1} & \text{if } T_g + T_{G2+M} + \frac{1}{2}T_s \leq t \end{cases}$$

(2)

where $T_c$, $T_{G2+M}$ and $T_s$ are the durations of the total cell cycle, or the individual phases (G2+M) and S, which must be estimated experimentally or assumed. If $p$ is the probability that a new cell is proliferating, then

$$c = \frac{\ln(2p)}{T_c}.$$

(3)

$p = 1$ corresponds to a growth fraction of 1, which is what we have assumed in this study. If a growth fraction less than unity is assumed it does not change any of the conclusions for time intervals less than G2+M+S. Equation (2) can then be used to calculate $f(t)$ for any time $t$ after injecting the stain. It is also possible to solve for $T_s$ for a known $f(t)$ and $t$, with an assumed $T_g$ and $T_{G2+M}$.

Then, by setting $t = 0$, one can calculate the true LI.

**Analysis of human tumours**

We have taken two sets of flow cytometry data for human tumours that have already been published (Bergström et al, 1998; Palmqvist et al, 1998). We have re-considered the data from bivariate histograms, i.e. the corrected LI and the correction factor. These were originally obtained by gating labelled cells that were considered by the FCM operator to have divided in the interval between administering the precursor and surgical excision. Using the simple practical correction, these gated labelled G1 cells were halved (to correct for division) and subtracted from both the numerator and the denominator to obtain LI corrected. The two data sets have now been re-analysed. Using the actual raw count of LI a theoretical correction was applied from equation 2, calculated for the specific time from injection to surgery for that sample.

In order to undertake this more complex mathematical modeling it is necessary to specify the appropriate values for the cell cycle phase durations. These are listed in Table 1 for spontaneous human tumours and for a range of experimental models, determined by the per cent labelled mitosis method (Steel, 1977). The combined duration of the phases (G2 and mitosis) is the most important parameter for the present purposes, since cells labelled while in the S phase must transit these phases before appearing as two cells in G1. Using the per cent labelled mitosis curve method, $T_{G2+M}$ was found to be approximately three times longer in human

| Table 1 Average estimates of cell cycle phase durations obtained with the per cent labelled mitosis technique in solid tumours (from Steel, 1977) |
|-------------------------------------------------|
| **Tumour type** | **G1 (h)** | **S (h)** | **G2* (h)** | **LI (%)** |
|-----------------|-------------|------------|-------------|------------|
| Human tumours   | 22 (8–38)   | 16 (10–24) | 6 (2–10)    | 19 (4–29)  |
| Frequently passed mouse tumours               | 4 (2–7)     | 9 (6–12)   | 2 (1–5)     | 32 (12–68) |
| Frequently passed tumours in rats and hamsters| 11 (4–39)   | 8 (5–10)   | 3 (1–4)     | 20 (10–36) |
| Early transplants of tumours in rats and mice | 13 (4–48)   | 11 (4–18)  | 2 (1–4)     | 18 (5–45)  |
| Primary tumours (animals)                     | 13 (2–36)   | 8 (5–11)   | 3 (1–6)     | 14 (6–31)  |

*Time in mitosis is approximately 1 h in experimental systems. Arithmetic mean of quoted values with range shown in brackets.
tumours (mean value 6 h) than in rodents. Using flow cytometry techniques somewhat shorter TG2+M estimates have been found, e.g. 4.5 h (Begg, 1989). A range of possible TG2+M values have therefore been used for our calculations.

**RESULTS**

Figure 1 illustrates the cyclic fluctuations in the observed LI values if the interval between labelling and sampling is varied between 1 h and 30 h. In this example we have used representative values for LI of 15%, TG2+M of 6 h and TS of 15 h. The upper panel (Figure 1A) shows that the LI falls from the starting value of 15% for a period corresponding to TG2+M, during which time unlabelled cells divide, and then increases as cells originally labelled in S pass through mitosis. (B) This leads to fluctuations in the factor needed to convert the observed LI at time T to the true LI at time = 0. An upward correction (> 1.0) is needed at times shorter than TG2+M.

Figure 2 shows how the correction factor depends upon the chosen parameters. In general, the default values for these calculations have been set at LI0 = 15%, TG2+M = 6 h and TS = 15 h. In each panel two of these parameters are kept constant and the third is varied systematically to determine its impact. The graphical display is now limited to the region of clinical interest, i.e. the first 10 h. (The recommended interval between labelling and obtaining the tumour specimen by biopsy or surgery is 4–8 h.)

Figure 2A shows the major influence of the duration of G2+M. Unlabelled cells transit mitosis and produce an artificial reduction in the observed LI for a period that is a little longer than TG2+M. Thus a positive correction is needed to increase LI to its original value for longer intervals if the duration of TG2+M is longer. The correction factor is small, and does not reach 10% in these examples.

Figure 2B shows that the value of TS has no influence on the time period for which an upward correction is needed, but it does have an influence on the magnitude of the actual correction factor.

6 h (i.e. TG2+M) because of addition by division of unlabelled cells. In this example, only after 7 h is a downward correction needed.

Figure 2B shows how the correction factor depends upon the chosen parameters. In general, the default values for these calculations have been set at LI0 = 15%, TG2+M = 6 h and TS = 15 h. In each panel two of these parameters are kept constant and the third is varied systematically to determine its impact. The graphical display is now limited to the region of clinical interest, i.e. the first 10 h. (The recommended interval between labelling and obtaining the tumour specimen by biopsy or surgery is 4–8 h.)
For this threefold change in $T_s$ the correction factors are all small (≤10%), but positive, for a little longer than the duration of G2+M.

Figure 2C shows the impact of the choice of LI₀ for these schematic illustrations. The correction factor in the early time intervals varies in proportion to the fraction of unlabelled cells at the start. For higher LI₀ values, unlabelled cells are rarer, and the addition of extra unlabelled cells from G2 has a greater impact. The magnitude of the correction is directly proportional to LI₀ and stays positive for a longer time with higher labelling indices.

Table 2 is a nomogram to illustrate correction factors calculated for a range of LI values and sampling times.

| $T_{G2+M}$ = 6 h LI₀ | 5% | 10% | 15% | 20% | 25% | 30% | 35% |
|---------------------|----|-----|-----|-----|-----|-----|-----|
| Time                |    |     |     |     |     |     |     |
| 2 h                 | 1.01 | 1.02 | 1.02 | 1.03 | 1.03 | 1.04 | 1.04 |
| 3 h                 | 1.03 | 1.03 | 1.03 | 1.04 | 1.04 | 1.05 | 1.06 |
| 4 h                 | 1.03 | 1.03 | 1.04 | 1.05 | 1.06 | 1.07 | 1.08 |
| 5 h                 | 1.00 | 1.00 | 1.02 | 1.03 | 1.05 | 1.06 | 1.07 |
| 6 h                 | 0.94 | 0.95 | 0.97 | 0.98 | 1.00 | 1.02 | 1.03 |
| 7 h                 | 0.89 | 0.90 | 0.92 | 0.94 | 0.96 | 0.97 | 0.99 |
| 8 h                 | 0.85 | 0.86 | 0.87 | 0.89 | 0.92 | 0.93 | 0.95 |

| $T_{G2+M}$ = 4.5 h LI₀ | 5% | 10% | 15% | 20% | 25% | 30% | 35% |
|---------------------|----|-----|-----|-----|-----|-----|-----|
| Time                |    |     |     |     |     |     |     |
| 2 h                 | 1.01 | 1.02 | 1.02 | 1.03 | 1.03 | 1.04 | 1.04 |
| 3 h                 | 1.03 | 1.03 | 1.03 | 1.04 | 1.05 | 1.05 | 1.06 |
| 4 h                 | 1.03 | 1.03 | 1.04 | 1.05 | 1.06 | 1.07 | 1.08 |
| 5 h                 | 1.00 | 1.00 | 1.02 | 1.03 | 1.05 | 1.06 | 1.07 |
| 6 h                 | 0.94 | 0.95 | 0.97 | 0.98 | 1.00 | 1.02 | 1.03 |
| 7 h                 | 0.89 | 0.90 | 0.92 | 0.94 | 0.96 | 0.97 | 0.99 |
| 8 h                 | 0.85 | 0.86 | 0.87 | 0.89 | 0.92 | 0.93 | 0.95 |

| $T_{G2+M}$ = 3 h LI₀ | 5% | 10% | 15% | 20% | 25% | 30% | 35% |
|---------------------|----|-----|-----|-----|-----|-----|-----|
| Time                |    |     |     |     |     |     |     |
| 2 h                 | 1.02 | 1.02 | 1.03 | 1.03 | 1.04 | 1.05 | 1.06 |
| 3 h                 | 1.03 | 1.03 | 1.04 | 1.05 | 1.05 | 1.06 | 1.07 |
| 4 h                 | 0.97 | 0.97 | 0.98 | 0.99 | 1.00 | 1.01 | 1.02 |
| 5 h                 | 0.91 | 0.92 | 0.93 | 0.94 | 0.96 | 0.97 | 0.98 |
| 6 h                 | 0.87 | 0.87 | 0.88 | 0.90 | 0.92 | 0.93 | 0.95 |
| 7 h                 | 0.82 | 0.83 | 0.84 | 0.86 | 0.88 | 0.90 | 0.91 |
| 8 h                 | 0.77 | 0.79 | 0.80 | 0.82 | 0.84 | 0.86 | 0.88 |

between injection and surgery. Since it has been specified that the appearance of a subset of divided labelled cells is a necessary ‘quality control’ feature for the relative movement assay (Begg, 1989) an effort is always made to identify and gate out the G1 cells in the bivariate histograms. In the left-hand histogram, although there is no clear margin between the two gates, they have nevertheless been defined, setting a gate over the G1 peak. We now believe that the frame applied in the left hand panel is inappropriate because it assumes cell division of labelled cells in an interval that is too short to allow that. These cells must be undivided early S phase labelled cells. In this very short interval between labelling and surgical excision, it is extremely unlikely that any labelled cells could have traversed G2 and mitosis. In the right-hand panel, by contrast, there is a clear zone between the two clouds of labelled cells, and this histogram shows that a significant fraction of S phase cells have divided in this tumour within 6.4 h. These gating procedures, as shown, are routinely applied within our pathology department.

We have taken two recently published sets of data from our institution in which we have re-evaluated each flow cytometry histogram to obtain each raw uncorrected value of LI. We have then replaced the simple gating correction factors with those calculated as in Table 2. Figure 4 shows the factors that were originally applied by FCM gating to correct each data point in these two published series of colon and rectal tumours. They range from 0.63 to 0.95 and show remarkably little dependence upon the time interval between injection and tumour excision. The bold solid line shows the correction factor that should theoretically apply if $T_{G2+M}$ is as short as 4.5 or even 3 h. It is clear that almost all of the correction factors that were applied by the simple gating procedure are in disagreement with the more precise mathematical prediction. Even if the G2+M were as short as 3 h (lower dashed line), all but three of the correction factors should not be as low as those that have in practice been applied.

Figure 5 illustrates the individual LI values obtained with the two different methods of correcting for cell division. In the left hand panels the data are illustrated, divided according to the time interval, for short, average and long intervals. There is a consistent deviation of the points away from the 1:1 correlation independent of the interval between injection and surgery. The right hand panels show that the rank order is similar but not identical for the LI corrected by the two methods.

Figure 6 illustrates the consequence of these two different approaches to correcting LI and compares them with the raw data. Cumulative frequencies of LI are shown, and the median value is indicated at 50% on each curve. Figure 6A represents 34 rectal carcinomas and Figure 6B 53 colon carcinomas. The median LI values corrected by the mathematical modelling technique are almost identical to the raw data. However, the median values after correction by the FCM gating technique are 27–31% lower compared with the original raw data. The progressive separation of the curves at higher values of LI shows the increasing influence of the addition of unlabelled cells by division at early times if they are relatively rare in the population. Figure 6 clearly demonstrates that for these two sets of data the raw uncorrected LI are more accurate than those to which the simple FCM gating correction has been applied.

The means and ranges derived from the publications where these data were originally reported are summarized in Table 3 (rectal tumours, Bergström et al, 1998, and colorectal tumours, British Journal of Cancer (1999) 80(10), 1635–1643 © 1999 Cancer Research Campaign
The choice of correction factor makes a substantial difference to the conclusion about the mean LI and the range in both these data sets. The mathematically corrected LI values do not change much even if \( G_2 + M \) is varied between 3 and 6 h. They are all quite close to the uncorrected value and differ markedly from those derived with a simple FCM correction. This indicates that less error is introduced if no correction factor is applied.

**DISCUSSION**

The technical innovation of being able to use a single biopsy to simultaneously measure \( T_s \) and LI has made it possible to accumulate a large amount of data on human tumour cell kinetics. Many thousands of patients have now received one of the halogenated pyrimidines and most of the studies have shown that the LI is very variable from patient to patient, and from one histological type and
The flow cytometric estimates of the potential doubling time from these relative movement assays show that the median $T_{pot}$ is around 4–7 days for most tumour types, but with a spread from 1 to 30 or more days. The duration of $T_{pot}$ is directly linked to the estimate of LI. Thus any underestimate of LI, because of the inappropriate use of the simple gating correction factor would translate into a corresponding overestimate of the potential doubling time. This is a minor variation compared with the 10- to 20-fold difference from volume doubling times but still may be important for practical purposes. The absolute values of $T_{pot}$ are now being built into many predictive models of the consequences of fractionation using shorter treatment schedules (e.g. Fowler and Lindström, 1992). Tumours are sometimes classified as ‘fast’ if their $T_{pot}$ value is shorter than 5 days and ‘slow’ if it is longer. The systematic ‘down correction’ of LI would change the proportions in these two categories and hence the need for selection of patients for accelerated regimes.

Several large studies are in progress to evaluate the relationship between the estimate of LI or $T_{pot}$ and the outcome of treatment with either a conventional or an accelerated regime (e.g. Begg et al, 1999; P Coucke et al, unpublished data). These are designed to determine whether these kinetic parameters are useful prognostic or predictive markers. The ultimate goal is to be able to identify those patients at most risk of proliferation during a course of therapy and select those for an accelerated regime. For this reason it is very important to avoid random or systematic errors creeping into the measurements, or differences in analytical procedures from one centre to another.

It has long been recognized that the long interval needed between injection and sampling of the tumour for the relative movement assay may necessitate a correction of LI (Begg, 1989). The simple practical solution that is commonly applied, however, totally ignores the contribution of unlabelled G2 cells as they divide. It focuses only on the artefact of additional labelled cells, as those from the labelled compartment transit through G2 and mitosis. It has been stressed that this is inappropriate if the time between injection and sampling is too short and will give an underestimate (Begg, 1988; Wilson et al, 1988). It then becomes very important to consider how short is too short, and for this Figure 2 shows that the duration of G2+M is the crucial parameter.

Table 1, containing data from the comprehensive review by Steel (1977), shows that the estimates obtained from human tumours in the 1970s, using the very detailed studies of multiple biopsies after administering tritiated thymidine, range from 2 to 10 h with an average of 6 h. Begg (1989), however, deduced a value slightly lower than this average. He considered the fraction of tumours with clear movement of labelled cells into G1 as a function of the time after administering bromodeoxyuridine (BrdU), and reported an average value of 4.5 h.

Figure 7 summarizes three sets of data from which the duration of G2+M can also be derived. One set is from a single centre (Amsterdam) assessment of all the tumours entered into the multi-centre randomized EORTC accelerated radiotherapy trial (Begg et al, 1998). It shows that about 80% of the tumours are considered to
have divided labelled cells in G1 by 4 h and 100% by 4.5 h. The second set of data comes from a single-centre study in Cairo by Awwad and colleagues, for which all the data have been analysed in Amsterdam (unpublished). It shows 85% of the tumours having been described as having labelled divided cells at 4 and 5 h, and all by 5.5 h. Both data sets would imply a G2+M that is shorter than 4 h in many human tumours. The Umeå data in Figure 6 are clearly in disagreement with those from Amsterdam since they show that all tumours were considered to have labelled G1 cells regardless of the interval between labelling and sampling. This is biologically unrealistic.

The practice of gating divided labelled cells seems to differ from centre to centre. The details of the method and the resultant correction factor is not quoted in publications, and is therefore...
difficult to determine from any published series. It is then impossible to rederive the original values. At the Gray Laboratory the average correction factor applied in a large series of patients is 0.88, but in 25% of the patients it is as low as 0.83 (GD Wilson, personal communication). At Amsterdam the average correction factor is 0.89 over a large series of patients. Table 2 would indicate such values are only applicable at labelling times beyond 6 h if TG2+M is 3.0 h or longer.

White and colleagues long ago recognized that any simple correction is inappropriate and have proposed a series of more complex formulae to correct with greater accuracy (White et al, 1990; Terry and Peters, 1995). Their approach is the same as the one we have adopted here and requires assumptions be made about phase length durations. They assume, however, that the duration of G2+M is 30% of S. It is clear that their approach is more accurate and will provide a truer estimate of the initial LI. Most of the practitioners of flow cytometry have found the simple practical solution more appealing than attempting to incorporate the more complex mathematics. The use of the nomogram in Table 2 or the curves in Figures 2 and 4 provide a simple means of checking if the correction factor is reasonable before it is applied.

The issue of the method of correcting LI obtained at late sampling time to the value that was relevant at time zero has recently been addressed in detail by Johansson et al (1998). Using data from in vitro experiments they have intercompared four different correction techniques to see which would give the smallest change of corrected LI with sampling time. They show marked differences between four mathematical models, three of which purport to correct for the addition by division of both unlabelled (G2) cells and labelled (S) cells. There is a 20% difference in the corrected LI that they calculate with these four formulae. Most of the corrected values differ significantly from the LI values they have actually observed with a very short labelling interval. This amply illustrates the problem but does not provide a general solution.

We have attempted in this paper to illustrate graphically the concept behind the need for a mathematical correction factor in order to demonstrate the parameters that influence the magnitude of that correction. We have illustrated that the ‘simple’ correction is unreasonable unless very short TG2+M values are relevant in human tumours, or quite long intervals are used between labelling and excision. Samples taken at short intervals, less than the duration of G2, are therefore most at risk from this underestimation of LI.

When large series of patients are reported, all the information about the details of time between injection and sampling is, of course, lost in the averaging procedures. Figure 6 shows that the uncorrected data are actually very close to the mathematically corrected data, since the correction factor rarely exceeds 1.1. In these studies, 29% of the tumour samples were taken at intervals
outside of the recommended labelling time of 4–8 h. Twenty-two per cent were taken at shorter times and 7% at longer times. The median time of biopsy was 5.3 h and the median correction factor applied was 0.73. We suggest that the provision of the raw uncorrected data should be recommended in all publications. We also suggest that every correction factor derived ‘blindly’ for the sample in the flow cytometer should be cross-checked against a nomogram such as those in Table 2 to see whether it is a reasonable figure, taking into account the interval between injection and surgery/biopsy. This could certainly lead to overestimations of $T_{pot}$ and a false perception of the speed of tumour cell proliferation.

CONCLUSION

We conclude that the simple application of a gating procedure to correct LI values obtained many hours after labelling may be hazardous. In our institute it produces a 27% reduction in the median LI values compared with the raw data. This underestimation of LI in human tumours may be a common systematic artefact in other laboratories. We would urge those groups collecting LI values for the assessment of their prognostic or predictive value to reconsider the correction factors that have been applied. Application of an inappropriate correction factor, especially for the short sample times could reduce the apparent prognostic power of LI as a proliferation marker, simply because any true correlation may be obscured.

ACKNOWLEDGEMENTS

We are grateful to Prof. Hassan Awwad for allowing us to use his flow cytometry data to derive $T_{G2}$ values. We are grateful to the Umeå Cancerforskningsfond for financial support and to Bo Littbrand and Roger Stenling for encouragement and for stimulating discussions.

REFERENCES

Begg AC (1989) Derivation of cell kinetic parameters from human tumours after labelling with bromodeoxyuridine. Br J Radiol Report 19: 113–119
Begg AC (1995) The clinical status of $T_{pot}$ as a predictor? Or why no tempest in the $T_{pot}$? Int J Radiat Biol Phys 32: 1539–1541
Begg AC, McNally NJ, Shrieve DC and Kärcher H (1983) A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6: 620–626
Begg AC, Moonen L, Hogland I, Dressing M and Bartelink H (1988) Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations. Radiother Oncol 11: 337–347
Begg AC, Haustermans K, Hart AAM, Dische S, Saunders M, Zackrisson B, Gustafsson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot JC, Corvo R, Giaretti W, Awwad H, Shouman T, Joffroy T, Maciorowski Z, Dobrowsky W, Struikmans H and Wilson GD (1999) The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol (in press.)
Bergström C, Palmqvist R, Denekamp J, Öberg Å, Tavelin B and Stenling R (1998) Factors influencing the estimates of proliferative labelling indices in rectal cancer. Radiother Oncol 46: 169–177
Bennett MH, Wilson GD, Dische S, Saunders MI, Martinadle CA, Robinson BM, O’Halloran AE, Leslie MD and Laing JHE (1992) Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer 65: 870–878
Brons PPT, Raemaekers JMM, Bogman MJJT, Van ERP PEJ, Boezeman JBM, Pennings AHM, Wessels HNC and Haanen C (1992) Cell cycle kinetics in malignant lymphoma studied with in vivo iododeoxyuridine administration, nuclear Ki-67 staining, and flow cytometry. Blood 80: 2336–2343
Dolbeare FA, Gradner HG, Pallavicini MG and Gray JW (1983) Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 80: 5573–5577
Fowler JF and Lindstrom MJ (1992) Loss of control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23: 457–467
Grazer HG (1982) Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 218: 474–475
Howard A and Pelo SR (1953) Synthesis of deoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. Heredity (Edinburg) 6: 261–277
Johansson MC, Johansson R, Baldestor B and Oredsson SM (1998) Comparison of different labelling index formulae used on bromodeoxyuridine flow cytometry data. Cytometry 32: 233–240
Palmqvist R, Öberg Å, Bergström C, Rutegärd JN, Zackrisson B and Stenling R (1998) Systematic heterogeneity and prognostic significance of cell proliferation in colorectal cancer. Br J Cancer 77: 917–925
Rew DA, Wilson GD, Taylor I and Weaver PC (1991) Proliferation characteristics of human colorectal carcinomas measured in vivo. Br J Surg 78: 60–66
Steel GG (1977) Growth Kinetics of Tumours. Oxford University Press: London.
Terry NHA, Meistrich ML, Roubein LD, Lynch PM, Dubrow RA and Rich TA (1995) Cellular kinetics in rectal cancer. Br J Cancer 72: 435–441
Terry NHA and Peters LJ (1995) The predictive value of tumour-cell kinetic parameters in radiotherapy. Considerations regarding data production and analysis. J Clin Oncol 13: 1833–1836
White RA, Terry NHA and Meistrich ML (1990) New methods for calculating kinetic properties of cells in vitro using pulse labelling with bromodeoxyuridine. Cell Tissue Kinet 23: 561–573
Wilson GD, McNally NJ, Dische S, Saunders MI, Des Rochers C, Lewis AA and Bennett MH (1988) Measurement of cell kinetic parameters in human tumours in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer 58: 423–431
Wilson GD (1993) Limitations of the bromodeoxyuridine technique for measurement of tumour proliferation. In: Medical Radiology, Current Topics in Clinical Radiobiology of Tumours, Beck-Bornholdt HP (ed), pp. 27–43. Springer-Verlag: Berlin.
Wilson MS, West CML, Wilson GD, Roberts SA, James RD and Schofield PF (1993) An assessment of the reliability and reproducibility of measurement of potential doubling times $(T_{pot})$ in human colorectal cancers. Br J Cancer 67: 754–759
Wilson MS, West CML, Wilson GD, Roberts SA, James RD and Schofield PF (1993) Intra-tumoural heterogeneity of tumour potential doubling times $(T_{pot})$ in colorectal cancer. Br J Cancer 68: 501–506

© 1999 Cancer Research Campaign

British Journal of Cancer (1999) 80(10), 1635–1643